PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 6, 20260 citationsOpen Access

Artificial Intelligence in the Pharmaceutical Industry: Applications, Future of Clinical Pharmacy Challenges and Technology Drug Delivery Design

View Full Paper
AKAdarsh Pratap Singh1, Sandeep Prakash*1, Saurabh Kumar1, Neha Gautam1, Firdous Bano1, Harshit Gupta1, Lavkush Maurya1, Sandeep Kumar1, Sneh Lata1, Ajay Kmar1

Key Points

  • This review evaluates the role of artificial intelligence in pharmaceutical innovation and its challenges.
  • Comprehensive review of literature from 2013 to 2026
  • Synthesis of insights from interdisciplinary studies
  • Analysis of case studies on AI applications in drug development
  • AI enhances drug discovery and clinical development processes
  • AI applications are evident in personalized medicine and pharmacovigilance
  • Challenges include algorithmic bias and the black-box nature of AI models

Abstract

Artificial intelligence (AI), machine learning (ML), and deep learning (DL) are gaining increased interest in many fields, into pharmaceutical Research has catalyzed transformative advancements across drug discovery, clinical development, manufacturing, and postmarket surveillance. This review comprehensively examines AI's role in modern pharmacotherapy, beginning with its historical evolution in life sciences and progressing to cutting-edge applications such as AlphaFolddriven protein modeling, natural language processing (NLP) for biomedical literature mining, and AIaugmented pharmacovigilance. Methodologically, we synthesize interdisciplinary insights from peer-reviewed literature (2013–2026), highlighting innovations in cheminformatics (e.g., QSAR, RDKit), predictive toxicology, and personalized medicine. Case studies illustrate AI's capacity to compress drug development timelines, as seen in COVID-19 repurposing efforts and de novo kinase inhibitor design. However, challenges persist, including algorithmic bias, regulatory ambiguities, and the “black-box” nature of deep learning models. By critically evaluating successes and limitations, this review underscores AI's potential to redefine pharmaceutical innovation while advocating for robust frameworks to ensure ethical, transparent, and clinically translatable AI deployment

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Adarsh Pratap Singh1, Sandeep Prakash*1, Saurabh Kumar1, Neha Gautam1, Firdous Bano1, Harshit Gupta1, Lavkush Maurya1, Sandeep Kumar1, Sneh Lata1, Ajay Kmar1 (2026) studied this question.

synapsesocial.com/papers/69fa989404f884e66b532555https://doi.org/10.5281/zenodo.20023466
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1ARTIFICIAL INTELLIGENCE IN THE PHARMACEUTICAL INDUSTRY: APPLICATIONS, FUTURE OF CLINICAL PHARMACY CHALLENGES AND TECHNOLOGY DRUG DELIVERY DESIGN2026
  2. 2ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL SCIENCES: APPLICATIONS, METHODOLOGIES, AND FUTURE TRENDS IN DRUG DISCOVERY AND HEALTHCARE2026
  3. 3PHARMACEUTICAL SCIENCE IN THE ERA OFARTIFICIAL INTELLIGENCE2026
  4. 4COMPREHENSIVE REVIEW ON AI IN THE PHARMACEUTICAL INDUSTRY: NEW IDEAS, USES, AND WHAT THE FUTURE HOLDS2026
  5. 5Artificial Intelligence in Pharmaceuticals2026